Quantcast

Latest Diabetic retinopathy Stories

2011-08-31 11:27:46

A simple finger prick test during routine eye examinations at high street opticians could help to identify millions of people with previously undiagnosed Type 2 diabetes, according to new research. The researchers suggest earlier diagnosis could set people on the road to better management of the disease, which is the leading cause of blindness in the working age population, and that this could ultimately result in cost-savings for the NHS. The Durham University study suggests that...

2011-08-17 15:05:00

TARRYTOWN, N.Y., Aug. 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that clinical data from four separate clinical studies of EYLEA(TM) (aflibercept injection) will be presented at the upcoming American Society of Retina Specialists (ASRS) meeting on Sunday, August 21 and Monday, August 22, 2011 in Boston, Massachusetts. The presentations are: "Analysis of 2,457 Patients in the Phase 3 VIEW 1 and VIEW 2 Studies Comparing VEGF Trap-Eye and...

2011-08-17 10:08:00

ANN ARBOR, Mich., Aug. 17, 2011 /PRNewswire-USNewswire/ -- Many Americans suffer from diabetes and hypertension and, according to a study by researchers at the University of Michigan Kellogg Eye Center, these individuals may have an increased risk of developing open-angle glaucoma (OAG). Joshua D. Stein, M.D., M.S., a glaucoma specialist at Kellogg, led a research team that recently reviewed billing records of more than 2 million people aged 40 and older who were enrolled in a managed care...

2011-08-16 16:10:00

TARRYTOWN, N.Y., Aug. 16, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the agency has extended its target date to complete the priority review of the EYLEA Biologics License Application (BLA) for the treatment of neovascular age-related macular degeneration (wet AMD) to November 18, 2011, which is a three month extension from the original Prescription Drug User...

2011-08-04 06:00:00

HONOLULU, Aug. 4, 2011 /PRNewswire/ -- Retina Institute of Hawaii (RIH) teams up with Paddleboard Race winner, Jamie Mitchell and Project VISION Hawaii. The partnerships are a tribute to passion and vision. Jamie celebrates his personal victory as 10th consecutive winner of the Molokai 2 Oahu Ocean competition and Retina Institute of Hawaii celebrates 10 years of treating macular degeneration, glaucoma, diabetic retinopathy and raising awareness of eye protection. Both Mr. Mitchell and...

136ed056a94d3b913b0f2c1153ea71fa
2011-06-17 10:25:00

After being hit by a thrown rock in the 1950s when he was just eight-years-old, a man had his vision restored after being treated for glaucoma, The Telegraph is reporting. The unnamed man, now 63 years of age, entered the New York Eye and Ear Infirmary complaining of persistent pain and redness in the blind eye. Doctors found he had glaucoma and high eye pressure. Once his eye pressure had stabilized they treated the neovascular glaucoma using monoclonal antibody therapy and found that...

2011-06-17 06:05:00

TARRYTOWN, N.Y., June 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that NASDAQ has halted trading of the company's common stock today. The Dermatologic and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is meeting today to discuss the company's Biologics License Application (BLA) for EYLEA(TM), also known as VEGF Trap-Eye, for the treatment of the neovascular form of age-related macular degeneration (wet AMD)....

2011-06-07 01:30:00

TARRYTOWN, N.Y. and BERLIN, June 7, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Regeneron and Bayer HealthCare are collaborating on the global development of VEGF Trap-Eye for the treatment of wet AMD, central retinal vein occlusion...

2011-06-05 18:01:00

MARLOW, England, June 6, 2011 /PRNewswire/ -- Allergan announces today that the National Institute for Health and Clinical Excellence (NICE) has recommended OZURDEX(R) (dexamethasone 0.7mg intravitreal implant in applicator) for the treatment of macular oedema due to central retinal vein occlusion (CRVO) and also for branch retinal vein occlusion (BRVO) where laser photocoagulation is neither beneficial nor appropriate. RVO is an eye condition that can lead to severe damage to the...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'